Skip to content
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting preparation
      • Outstanding shares and voting rights
      • Reports on Regulated Agreements and Commitments
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • English
  • French
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting preparation
      • Outstanding shares and voting rights
      • Reports on Regulated Agreements and Commitments
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Category Archives: News

You are here:
  1. Home
  2. Category "News"

Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference

2019By Alexis BERNARDMarch 21, 2019

21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.

Update on the restructuring of the AB Science clinical development department in 2018

2018By Alexis BERNARDDecember 19, 2018

19/12/2018 – AB Science provides the main achievements of this restructuring.

Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment

2018By Alexis BERNARDOctober 22, 2018

22/10/2018 – Final results will be available in 2019.

Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis

2018By Alexis BERNARDOctober 8, 2018

08/10/2018 – Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib’s mode of action in ALS.

First half of 2018 revenues

2018By Alexis BERNARDOctober 1, 2018

01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.

Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer

2018By Alexis BERNARDJuly 23, 2018

23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed.

Results of the Combined General Shareholders’ Meeting held on June 29 2018

2018By Alexis BERNARDJuly 3, 2018

03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.

Combined General Shareholders’ Meeting held on June 29, 2018

2018By Alexis BERNARDJuly 3, 2018

03/07/2018 – Presentation of the current situation and future prospects.

Positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer

2018By Alexis BERNARDJune 19, 2018

19/06/2018 – AB Science expects study to be completed in 2019.

Update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis

2018By Alexis BERNARDMay 28, 2018

28/05/2018 – AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015.

1
2345
…678910
AB Science
© AB Science – All right reserved
Go to Top